PA
BDTX icon

Parallel Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Parallel Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-298
Closed -$3K – 3087
2021
Q3 		$3K Buy
+298
New +$2.94K ﹤0.01% 2543

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's BDTX Position: Q4 2021 in Review

Parallel Advisors sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 298 shares — an estimated $3K sold.

Parallel Advisors first reported a position in BDTX in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • Parallel Advisors reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parallel Advisors sold 298 Black Diamond Therapeutics shares in Q4 2021, an estimated $3K.
  • Parallel Advisors first reported a position in Black Diamond Therapeutics in Q3 2021 and held it in 1 quarter.
  • Parallel Advisors's Black Diamond Therapeutics position peaked at $3K in Q3 2021.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.